SIP started deployment for biomedical industry in 2007. Since then, the industry has maintained an annual growth of more than 20% in total output value, which reached RMB 90 billion last year. This has enabled SIP to rank among the country’s best clusters of biomedicine businesses. Statistics show that SIP recorded a long list of new drugs that received approvals last year for clinical trials, which account for 10% of the national total, and of them, new biological drugs developed in SIP accounted for 20% of the national total.
[MORE]
